xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05979779</url>
    </required_header>
    <id_info>
      <org_study_id>RIV-HU6-2202</org_study_id>
      <nct_id>NCT05979779</nct_id>
    </id_info>
    <brief_title>Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Obese Subjects With Type 2 Diabetes at Risk of Nonalcoholic Steatohepatitis</brief_title>
    <official_title>A 6-Month, Randomized, Double-Blind, Placebo-controlled, Phase 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Obese Subjects With Type 2 Diabetes at Risk of Nonalcoholic Steatohepatitis</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Rivus Pharmaceuticals, Inc.</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Rivus Pharmaceuticals, Inc.</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose&#xD;
        levels of HU6 in obese subjects with type 2 diabetes (T2D) at risk of nonalcoholic&#xD;
        steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be&#xD;
        followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this&#xD;
        time. The end-of-study visit will take place approximately 4 weeks after the last dose of the&#xD;
        study drug (Week 30).&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose&#xD;
        levels of HU6 (150 mg, 300 mg, and 450 mg) and placebo in 280 obese subjects with T2D at risk&#xD;
        of NASH.&#xD;
  &#xD;
        Subjects will be screened over a 49-day period to determine their eligibility based on&#xD;
        specific history, physical, laboratory, and imaging evaluations, which will require more than&#xD;
        one visit during the screening period. On Day 1, subjects will be randomized 2:1:2:2 into 1&#xD;
        of 4 treatment groups (placebo, 150 mg HU6, 300 mg HU6, or 450 mg HU6). Six months (26 weeks)&#xD;
        of dosing is planned, and subjects will be followed for safety, efficacy, PD, and PK during&#xD;
        this time. The end-of-study visit will take place approximately 4 weeks after the last dose&#xD;
        of the study drug (Week 30).&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 2023</start_date>
    <completion_date type="Anticipated">November 2024</completion_date>
    <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
    <phase>Phase 2</phase>
    <study_type>Interventional</study_type>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <intervention_model_description>This is a Phase 2, randomized, parallel-group, placebo-controlled, double-blind study where subjects will be randomized to one of 3 HU6 dose levels or placebo.</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Percent change from baseline in liver fat, as assessed by magnetic resonance imaging liver proton density fat fraction (MRI-Liver PDFF) at 6 months (26 weeks)</measure>
      <time_frame>6 months</time_frame>
    </primary_outcome>
    <secondary_outcome>
      <measure>Percent change from baseline in body weight at 6 months (26 weeks)</measure>
      <time_frame>6 months</time_frame>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change from baseline in HbA1c at 6 months (26 weeks).</measure>
      <time_frame>6 months</time_frame>
    </secondary_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">280</enrollment>
    <condition>Non-Alcoholic Fatty Liver Disease</condition>
    <condition>Type 2 Diabetes</condition>
    <condition>Obesity</condition>
    <condition>Nonalcoholic Steatohepatitis</condition>
    <arm_group>
      <arm_group_label>Active Treatment: HU6 Planned doses of HU6</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
    </arm_group>
    <arm_group>
      <arm_group_label>Placebo Comparator Non-active study drug</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>HU6</intervention_name>
      <description>HU6 is being evaluated for its efficacy in improving liver fat content in obese subjects with Type 2 Diabetes at risk of Nonalcoholic Steatohepatitis (NASH)</description>
      <arm_group_label>Active Treatment: HU6 Planned doses of HU6</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>Placebo</description>
      <arm_group_label>Placebo Comparator Non-active study drug</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Able to understand the procedures and requirements of the study and provide written&#xD;
               informed consent and authorization for protected health information disclosure.&#xD;
  &#xD;
            2. Willing and able to comply with the requirements of the study protocol.&#xD;
  &#xD;
            3. Male or female ≥18 years of age at time of informed consent.&#xD;
  &#xD;
                 1. Female subjects of childbearing potential must be non-lactating, not pregnant as&#xD;
                    confirmed by a negative urine pregnancy test at Screening and Baseline, and&#xD;
                    using, and agree to continue using, an effective method of contraception for at&#xD;
                    least 4 weeks or double barrier method for 2 weeks prior to first study drug&#xD;
                    administration until 30 days after the last dose of study drug.&#xD;
  &#xD;
                 2. Female subjects of non-childbearing potential must be surgically sterile (e.g.,&#xD;
                    hysterectomy, bilateral tubal ligation, oophorectomy) or post-menopausal (no&#xD;
                    menses for &gt;1 year with follicle stimulating hormone [FSH] &gt;40 U/L at Screening).&#xD;
  &#xD;
                 3. Female subjects of childbearing potential must not donate ova during the study&#xD;
                    and for at least 30 days after the last dose of study drug.&#xD;
  &#xD;
                 4. Male subjects who have not had a vasectomy and/or subjects who have had a&#xD;
                    vasectomy but have not had 2 post-surgery negative tests for sperm must agree to&#xD;
                    use an acceptable method of contraception from time of first dose of study drug&#xD;
                    until 90 days after the last dose of the study drug, and to not donate sperm&#xD;
                    during the study and for at least 90 days after the last dose of study drug.&#xD;
  &#xD;
            4. Body mass index (BMI) ≥30.0 kg/m2.&#xD;
  &#xD;
            5. Subject has a screening Fibroscan®, CAP score &gt;306 decibels per meter (dB/m), and the&#xD;
               interquartile range (IQR) of the CAP &lt;30 dB/m.&#xD;
  &#xD;
            6. Any subject with a BMI and body weight of a magnitude that allows screening by&#xD;
               Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) must have ≥8% liver&#xD;
               fat determined by screening MRI-PDFF.&#xD;
  &#xD;
            7. Subject has T2D meeting all of the following criteria:&#xD;
  &#xD;
                 1. T2D diagnosis (based on American Diabetes Associate [ADA 2022a] Definition) ≥6&#xD;
                    months prior to Screening,&#xD;
  &#xD;
                 2. Screening HbA1c between 6.5% and 10.5%, inclusive, and&#xD;
  &#xD;
                 3. Subject is treated with diet and exercise alone -or- subject is receiving stable&#xD;
                    metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, and/or sodium-glucose&#xD;
                    transporter 2 (SGLT2) inhibitors (stable dose is defined as no change or &lt;50%&#xD;
                    change in dose within the 3-month period prior to screening).&#xD;
  &#xD;
            8. Has a history of at least one self-reported unsuccessful dietary effort to lose body&#xD;
               weight.&#xD;
  &#xD;
            9. Clinically euthyroid as assessed by a thyroid profile utilizing TSH and T4 testing at&#xD;
               screening as assessed by the investigator based on the medical history of the subject.&#xD;
               Subjects with a stable history of thyroid disease and who have been on stable doses of&#xD;
               thyroid medications for a minimum of 4 months can be enrolled. (Guidance to&#xD;
               Investigator: Generally, TSH values greater than 1.5× upper limit of normal (ULN) or&#xD;
               less than 1.5× lower limit of normal (LLN) would be exclusionary, but it needs&#xD;
               interpretation in the context of T4. In subjects with TSH values within these ranges,&#xD;
               there should be no evidence of clinically significant, insufficiently treated hyper-&#xD;
               or hypothyroidism that could be contributing to symptoms of dyspnea, exercise&#xD;
               intolerance, or weight changes in the opinion of the site investigator.).&#xD;
  &#xD;
           10. Subjects with a diagnosis of glaucoma must be controlled and stable (no changes in&#xD;
               treatment regimen within 3 months prior to Screening).&#xD;
  &#xD;
           11. Inclusion as per investigator assessment of general medical status and as documented&#xD;
               by medical history, physical examination, vital sign assessments, 12-lead ECG,&#xD;
               clinical laboratory assessments, and general observations.&#xD;
  &#xD;
                 1. At Screening, certain laboratory abnormalities are permissible if the abnormality&#xD;
                    is commensurate with the subject's underlying obesity or associated metabolic&#xD;
                    dysfunction (for example, dyslipidemia and hyperglycemia), unless the&#xD;
                    abnormalities suggest an underlying condition which may impact subject safety or&#xD;
                    interfere with the evaluation of HU6 or interpretation of the study results.&#xD;
  &#xD;
                 2. Note: Subjects with elevation of unconjugated bilirubin due to presumptive&#xD;
                    Gilbert's syndrome are permissible.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
          Subjects will be excluded from the study if any of the following criteria are met:&#xD;
  &#xD;
            1. Subject-reported history of weight gain or loss &gt;5% in 3 months prior to screening.&#xD;
  &#xD;
            2. Subject has &gt;10-pound weight loss between their screening and baseline visits.&#xD;
  &#xD;
            3. The subject has a history of cirrhosis and/or hepatic decompensation, including&#xD;
               ascites, hepatic encephalopathy, or variceal bleeding.&#xD;
  &#xD;
            4. The subject has a history of acute pancreatitis within 1 year of Screening or chronic&#xD;
               pancreatitis of any cause.&#xD;
  &#xD;
            5. History of any bariatric surgery intervention, including but not limited to lap&#xD;
               banding, intragastric balloon, duodenal-jejunal sleeve, or bariatric surgery or plans&#xD;
               for bariatric surgery prior to conclusion of study participation.&#xD;
  &#xD;
            6. Have obesity induced by other endocrinologic disorders (e.g., Cushing Syndrome,&#xD;
               polycystic ovarian syndrome) or diagnosed monogenetic or syndromic forms of obesity&#xD;
               (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).&#xD;
  &#xD;
            7. Any surgical or medical condition or history that, in the opinion of the investigator&#xD;
               in consultation with the medical monitor, may potentially alter the absorption,&#xD;
               metabolism, or excretion of study treatment.&#xD;
  &#xD;
            8. History of or treatment for clinically significant gastroparesis, inflammatory bowel&#xD;
               disease, or any surgery of the upper gastrointestinal tract with the exception of&#xD;
               cholecystectomy, or minor gastric procedures that are approved by the medical monitor.&#xD;
  &#xD;
            9. History (including any family history) of malignant hyperthermia.&#xD;
  &#xD;
           10. History of chronic serious recurrent skin rashes of unknown cause.&#xD;
  &#xD;
           11. History of malignancy within 5 years (except cutaneous basal or squamous cell&#xD;
               carcinoma, carcinoma-in-situ, or low-grade prostate cancer).&#xD;
  &#xD;
           12. History of the following cardiovascular conditions within 3 months prior to&#xD;
               randomization: acute myocardial infarction, cerebrovascular accident (stroke),&#xD;
               unstable angina, hospitalization due to congestive heart failure (CHF), or acute CHF.&#xD;
  &#xD;
           13. NYHA Functional Class II, III, or IV heart failure.&#xD;
  &#xD;
           14. Subject has a pacemaker.&#xD;
  &#xD;
           15. Active kidney disease requiring therapy, kidney transplant, or eGFR &lt;45 mL/min/1.73 m2&#xD;
               based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine&#xD;
               Equation (Inker 2021, Delgado 2022).&#xD;
  &#xD;
           16. Significant and unstable lung disease (chronic obstructive pulmonary disease [COPD],&#xD;
               emphysema, pulmonary fibrosis, or asthma) requiring oxygen or chronic daily&#xD;
               medication. Note that mild, stable COPD and asthma on inhalers are allowed.&#xD;
  &#xD;
           17. Subject has a diagnosed history of obstructive sleep apnea or uses continuous positive&#xD;
               airway pressure (CPAP).&#xD;
  &#xD;
           18. Subject has monogenetic diabetes or type 1 diabetes.&#xD;
  &#xD;
           19. Subject has a history of ketoacidosis or hyperosmolar state requiring hospitalization&#xD;
               in the 6 months prior to Screening.&#xD;
  &#xD;
           20. Subject has any history of agranulocytosis.&#xD;
  &#xD;
           21. Subject has Wilson's disease.&#xD;
  &#xD;
           22. Familial (mother/father/sibling) and/or personal history of retinal detachment any&#xD;
               time in the past.&#xD;
  &#xD;
           23. Subject has history of prior vitrectomy due to prior retinal condition.&#xD;
  &#xD;
           24. Subject has a contraindication to dilation for ophthalmologic examination.&#xD;
  &#xD;
           25. Evidence of the following on screening ophthalmologic examination:&#xD;
  &#xD;
                 1. Peripheral retinal pathology, retinal tears, lattice, or nondiabetic ocular&#xD;
                    condition that requires treatment or intervention within 3 months of Screening.&#xD;
  &#xD;
                 2. Diabetic retinopathy with macular exudates or macular edema (evidence of&#xD;
                    microaneurysms is not an exclusion).&#xD;
  &#xD;
                 3. Any active macular disease that affects the vision, including macular pucker&#xD;
                    (epiretinal membrane), retinal vein occlusion, and macular degeneration.&#xD;
  &#xD;
                 4. Subjects with significant visual impairment due to lens opacity from cataracts&#xD;
                    such that surgery will be required within the duration of the study in the&#xD;
                    opinion of the consulting ophthalmologist. (Subjects with cataract surgery &gt;3&#xD;
                    months prior to Screening may be included.)&#xD;
  &#xD;
                 5. Subject has substantial media opacities that preclude successful retinal imaging.&#xD;
  &#xD;
           26. Any condition (e.g., ongoing substance, drug, or alcohol abuse) that may interfere&#xD;
               with participation or safety of investigations, in the opinion of the Investigator.&#xD;
  &#xD;
           27. A history of moderate alcohol consumption defined as drinking ≥ 2 drinks per day for&#xD;
               men or ≥ 1 drink per day for women. (A drink is defined as 12 ounces of beer, 5 ounces&#xD;
               of wine, 1.5 ounces of distilled spirits.).&#xD;
  &#xD;
           28. Subjects with untreated, uncontrolled, or unstable hypertension (systolic blood&#xD;
               pressure [SBP] &gt;160 and/or diastolic blood pressure [DBP] &gt;100 mmHg upon repeat&#xD;
               evaluation at screening). If subject is treated with antihypertensive medication, the&#xD;
               regimen must be stable at least 1 month prior to screening.&#xD;
  &#xD;
           29. Subjects with untreated or persistent hypotension (SBP &lt;90 mmHg) or symptomatic&#xD;
               hypotension (that, in the opinion of the Investigator, requires active treatment).&#xD;
  &#xD;
           30. Tachycardia (&gt;100 beats/minute) at screening.&#xD;
  &#xD;
           31. QTcF &gt; 450 msec at screening for males and QTcF &gt; 470 msec at screening for females.&#xD;
  &#xD;
           32. Use of any of the following medications:&#xD;
  &#xD;
                 1. The following oral antidiabetic drugs are prohibited within 3 months prior to&#xD;
                    screening and continuing throughout the study: insulin, meglitinides,&#xD;
                    sulfonylureas, thiazolidinediones, glucagon-like peptide (GLP-1) agonists, and&#xD;
                    gastric inhibitory polypeptide (GIP)/GLP-1 agonists.&#xD;
  &#xD;
                 2. The following are prohibited within 3 months prior to screening (or planned use&#xD;
                    during the study) when used for weight loss: herbal preparation, over the counter&#xD;
                    (OTC) drug, mail order or prescription drug.&#xD;
  &#xD;
                 3. Prescription or OTC stimulants including: dextroamphetamine/Dexedrine,&#xD;
                    dextroamphetamine/amphetamine combination product/Adderall, or methylphenidate&#xD;
                    (Ritalin®, Concerta®).&#xD;
  &#xD;
                 4. Recent (within 3 months of screening) or current use of obeticholic acid/Ocaliva,&#xD;
                    systemic corticosteroids, methotrexate, tamoxifen, amiodarone, or long-term use&#xD;
                    of tetracyclines.&#xD;
  &#xD;
                 5. Warfarin, heparin, factor Xa inhibitors (e.g., dabigatran, betrixaban, edoxaban,&#xD;
                    apixaban, and rivaroxaban).&#xD;
  &#xD;
                 6. Vitamin E: use of ursodiol or high-dose vitamin E (&gt;400 IU/day) for at least 1&#xD;
                    month within the previous 6 months or started high dose vitamin E within the&#xD;
                    previous 3 months of Screening.&#xD;
  &#xD;
                 7. Drugs with high risk of idiosyncratic drug-induced neutropenia (IDIN) or&#xD;
                    agranulocytosis (Andres 2018, Curtis 2017): antithyroid drugs (propylthiouracil&#xD;
                    and methimazole), ticlopidine, clozapine, phenothiazines, sulfasalazine,&#xD;
                    vancomycin, amoxicillin, ceftriaxone, ciprofloxacin, cotrimaxozole,&#xD;
                    piperacillin-tazobactam, and trimethoprim-sulfamethoxazole (Bactrim® or Septra®).&#xD;
  &#xD;
                 8. Concomitant medications that prolong the QT/QTc interval and are known to be&#xD;
                    associated with increased risk of Torsade des pointes as identified in the&#xD;
                    https://crediblemeds.org/ website list category of 'Known Risk.'&#xD;
  &#xD;
           33. Have acute or chronic hepatitis, signs, and symptoms of any other liver disease other&#xD;
               than nonalcoholic fatty liver disease (NAFLD)/NASH, or any of the following, as&#xD;
               determined by the central laboratory during screening:&#xD;
  &#xD;
                 1. International normalized ratio (INR) ≥1.3, or&#xD;
  &#xD;
                 2. ALT &gt;5.0× the ULN for the reference range, or&#xD;
  &#xD;
                 3. AST &gt;5.0× the ULN for the reference range, or&#xD;
  &#xD;
                 4. Alkaline phosphatase (ALP) &gt;2.0× the ULN for the reference range, or&#xD;
  &#xD;
                 5. Total bilirubin &gt;1.2× the ULN for the reference range (except for cases of known&#xD;
                    Gilbert's Syndrome).&#xD;
  &#xD;
           34. Laboratory Values at Screening:&#xD;
  &#xD;
                 1. Hemoglobin &lt;9.5 g/dL, or&#xD;
  &#xD;
                 2. ANC ≤1500/μL, or&#xD;
  &#xD;
                 3. Marked hypertriglyceridemia (&gt;1000 mg/dL), or&#xD;
  &#xD;
                 4. Copper &lt;LLN for the reference range, or&#xD;
  &#xD;
                 5. Ceruloplasmin &lt;LLN for the reference range, or&#xD;
  &#xD;
                 6. Serologic evidence of hepatitis B based on hepatitis B surface antigen (HBsAG),&#xD;
                    or&#xD;
  &#xD;
                 7. Serologic evidence of hepatitis C antibody (HCV Ab) and HCV RNA, or&#xD;
  &#xD;
                 8. Serologic evidence of human immunodeficiency virus (HIV).&#xD;
  &#xD;
           35. Intolerance to MRI or with conditions contraindicated for MRI procedures including but&#xD;
               not limited to:&#xD;
  &#xD;
                 1. Having surgical clips/metallic implants/shrapnel -or-&#xD;
  &#xD;
                 2. Claustrophobia, have a history of claustrophobia, or intolerance of closed or&#xD;
                    small spaces.&#xD;
  &#xD;
           36. Participation in another clinical trial at the time of screening or exposure to any&#xD;
               investigational agent, including topical agents, within 30 days or 5 half-lives prior&#xD;
               to Day 1, whichever is longer.&#xD;
  &#xD;
           37. For subjects with a recent active viral, bacterial, or parasitic infection, they must&#xD;
               have discontinued any treatment for their infection at least 5 days prior to&#xD;
               screening. Patients who test positive for COVID-19 during the screening period must&#xD;
               have a negative rapid antigen test prior to randomization.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Diane Jorkasky, MD</last_name>
      <role>Study Director</role>
      <affiliation>Rivus Pharmaceuticals, Inc.</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Jasminder Soto</last_name>
      <phone>6173887757</phone>
      <email>jsoto@rivuspharma.com</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Janice Durden</last_name>
      <phone>8435683621</phone>
      <email>jdurden@rivuspharma.com</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Catalina Research Institute</name>
        <address>
          <city>Montclair</city>
          <state>California</state>
          <zip>91763</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Leslie Zaccari</last_name>
        <phone>714-366-6457</phone>
        <email>lzaccari@catalinari.com</email>
      </contact>
      <investigator>
        <last_name>Rizwana Mohseni, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Southwest General Healthcare Center</name>
        <address>
          <city>Fort Myers</city>
          <state>Florida</state>
          <zip>33907</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Yoel Santana</last_name>
        <phone>239-719-0157</phone>
        <email>info@swghealthcare.com</email>
      </contact>
      <investigator>
        <last_name>Jose Jose, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Panax Clinical Research</name>
        <address>
          <city>Miami Lakes</city>
          <state>Florida</state>
          <zip>33014</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Maria Revoredo</last_name>
        <phone>305-698-4500</phone>
        <email>mrevoredo@panaxcr.com</email>
      </contact>
      <investigator>
        <last_name>Robert Perry, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Advanced Clinical Research</name>
        <address>
          <city>Miami</city>
          <state>Florida</state>
          <zip>33156</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Leslye Perez</last_name>
        <phone>786-633-3081</phone>
        <email>lperez@aclinicalresearch.com</email>
      </contact>
      <investigator>
        <last_name>Lazro Garcia, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Century Research</name>
        <address>
          <city>Miami</city>
          <state>Florida</state>
          <zip>33173</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Osmel Nunez</last_name>
        <phone>786-351-7572</phone>
        <email>Osmel@centuryresearchllc.com</email>
      </contact>
      <investigator>
        <last_name>Alina Alvarez, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>Texas Liver Institute</name>
        <address>
          <city>San Antonio</city>
          <state>Texas</state>
          <zip>78215</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Joe Reidinger</last_name>
        <phone>210-253-3426</phone>
        <email>jreidinger@txliver.com</email>
      </contact>
      <investigator>
        <last_name>Eric Lawitz, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 31, 2023</study_first_submitted>
    <study_first_submitted_qc>July 31, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 7, 2023</study_first_posted>
    <last_update_submitted>July 31, 2023</last_update_submitted>
    <last_update_submitted_qc>July 31, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 7, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Liver Diseases</mesh_term>
      <mesh_term>Fatty Liver</mesh_term>
      <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
      <mesh_term>Diabetes Mellitus</mesh_term>
      <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05979779
  org study id: RIV-HU6-2202
  nct id: NCT05979779
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose
        levels of HU6 in obese subjects with type 2 diabetes (T2D) at risk of nonalcoholic
        steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be
        followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this
        time. The end-of-study visit will take place approximately 4 weeks after the last dose of the
        study drug (Week 30).
  This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose
        levels of HU6 (150 mg, 300 mg, and 450 mg) and placebo in 280 obese subjects with T2D at risk
        of NASH.
  
        Subjects will be screened over a 49-day period to determine their eligibility based on
        specific history, physical, laboratory, and imaging evaluations, which will require more than
        one visit during the screening period. On Day 1, subjects will be randomized 2:1:2:2 into 1
        of 4 treatment groups (placebo, 150 mg HU6, 300 mg HU6, or 450 mg HU6). Six months (26 weeks)
        of dosing is planned, and subjects will be followed for safety, efficacy, PD, and PK during
        this time. The end-of-study visit will take place approximately 4 weeks after the last dose
        of the study drug (Week 30).
  allocation: Randomized
  intervention model: Parallel Assignment
  intervention model description: This is a Phase 2, randomized, parallel-group, placebo-controlled, double-blind study where subjects will be randomized to one of 3 HU6 dose levels or placebo.
  primary purpose: Treatment
  masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  measure: Percent change from baseline in liver fat, as assessed by magnetic resonance imaging liver proton density fat fraction (MRI-Liver PDFF) at 6 months (26 weeks)
  time frame: 6 months
  measure: Percent change from baseline in body weight at 6 months (26 weeks)
  time frame: 6 months
  measure: Change from baseline in HbA1c at 6 months (26 weeks).
  time frame: 6 months
  arm group label: Active Treatment: HU6 Planned doses of HU6
  arm group type: Experimental
  arm group label: Placebo Comparator Non-active study drug
  arm group type: Placebo Comparator
  intervention type: Drug
  intervention name: HU6
  description: HU6 is being evaluated for its efficacy in improving liver fat content in obese subjects with Type 2 Diabetes at risk of Nonalcoholic Steatohepatitis (NASH)
  arm group label: Active Treatment: HU6 Planned doses of HU6
  intervention type: Other
  intervention name: Placebo
  description: Placebo
  arm group label: Placebo Comparator Non-active study drug
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Diane Jorkasky, MD
  role: Study Director
  affiliation: Rivus Pharmaceuticals, Inc.
  last name: Jasminder Soto
  phone: 6173887757
  email: jsoto@rivuspharma.com
  last name: Janice Durden
  phone: 8435683621
  email: jdurden@rivuspharma.com
  facility: 
  contact: 
  investigator: 
  facility: 
  contact: 
  investigator: 
  facility: 
  contact: 
  investigator: 
  facility: 
  contact: 
  investigator: 
  facility: 
  contact: 
  investigator: 
  facility: 
  contact: 
  investigator: 
  country: United States
  responsible party type: Sponsor
  mesh term: Liver Diseases
  mesh term: Fatty Liver
  mesh term: Non-alcoholic Fatty Liver Disease
  mesh term: Diabetes Mellitus
  mesh term: Diabetes Mellitus, Type 2
  sharing ipd: No